

RECEIVED CENTRAL FAX CENTER

## Facsimile Cover Sheet

To:

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

Fax:

(703) 872-9306

From:

Jeffrey A. Hagenah, Legal Dept.

Company:

Theravance, Inc.

901 Gateway Boulevard

South San Francisco, California 94080 USA

Telephone:

(650) 808-6406

Fax:

(650) 808-6078

Date:

April 12, 2005

# of pages:

3 pages

(Including this page)

Re:

U.S. Serial No. 09/847,048

Confirmation No. 5200

Attorney Docket No.: P-091-US1

entitled: Glycopeptide Disulfide and Thioester Derivatives

## **OFFICIAL PAPERS**

Att:

Power of Attorney and Corespondence Address Indication Form (1-page)

Statement Under 37 CFR 3.73(b) (1-page)

Certificate of Facsimile Transmission

I hereby certify that this correspondence is being transmitted on the date shown below via facsimile to the Commissioner for Patents, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 at the facsimile number indicated below.

Dated: April 12,2005

Facsimile Number: (703) 872-9306

## PRIVILEGED AND CONFIDENTIAL

## Notice of Confidentiality

The following transmittal contains confidential information intended exclusively for the abovenamed person. Use or disclosure of information transmitted in error is prohibited. Please call Theravance, Inc. at the above number if you have received this fax in error, and either destroy or return the faxed enclosures to us.

PTO/SB/96 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. STATEMENT UNDER 37 CFR 3.73(b) Applicant/Patent Owner: MU et al. Application No./Patent No.: 09/847,048 Filed/Issue Date: May 1, 2001 Entitled: Glycopeptide Disulfide and Thioester Derivatives Theravance, Inc. corporation (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.) 1. the assignee of the entire right, title, and interest; or 2. 
an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is\_ in the patent application/patent identified above by virtue of either: A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached. B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below: 1. From: Inventors To: Advanced Medicine, Inc. (Assignment document) The document was recorded in the United States Patent and Trademark Office at Reel 012169 , Frame 0279 \_, or for which a copy thereof is attached. 2. From: Advanced Medicine, Inc. To: Theravance, Inc. (Merger document) The document was recorded in the United States Patent and Trademark Office at Reel <u>013003</u>, Frame <u>0075</u> \_, or for which a copy thereof is attached. 3. From: To: The document was recorded in the United States Patent and Trademark Office at \_, Frame \_\_ \_, or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. Copies of assignments or other documents in the chaln of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. April | 2 2005 Stenature Date Hagenan, Reg. No. 35,175 (650) 808-6406 Printed or Typed Name Telephone Number Assistant Secretary of Thervance, Inc.

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons a	U.S. Patent and	PTO/SB/6 Approved for use through 11/30/2005. OMB de Trademark Office; U.S. DEPARTMENT OF COM Information unless it displays a valid OMB control	51-0035	
<i>(</i>	Application Number	09/847,048	A HOLLOGI.	•
POWER OF ATTORNEY	Filing Date	May 1, 2001	· · · · · · · · · · · · · · · · · · ·	1
and	First Named Inventor	MU et al.	RE	CEIVED
CORRESPONDENCE ADDRESS	Title	Glycopeptide Disulfide and Thioes Derivatives	ENTR	l fax centef
INDICATION FORM	Art Unit	1653	API	1 2 2005
	Examiner Name	KAM, Chih Min	<del>5-65-61</del>	1 2 2.000
	Attorney Docket Number	P-091-US1		}
				•

I hereby rev	oke all previous powers of attorr	nev given l	n the ab	ove-ide	entified ar	polication	
i hereby appoi						priodition	; :
☑ Practitioners associated with the Customer Number: OR			27038				: :
☐ Practitioner(s	s) named below:					_	•
ļ	Name		Registration Number				1
		_					i
			<u></u>		·		<u>.</u>
						1	
			·			1	•
as my/our attorne Patent and Trade	y(s) or agent(s) to prosecute the application mark Office connected therewith.	identified abo	ove, and to	transact :	all business i	ı n the United	States
Please recogniz	e or change the correspondence address for	the above-id	entified app	lication t	io:		:
	associated with the above-mentioned Custo						:
OR	s associated with Customer Number:						· : } :
OR		<u>-</u> -					
Firm or Individual Nam	ne				·		
Address					-		
City		State		ZIP	T		:
Country		<u></u>			<u> </u>		
Telephone		Fax	<del></del>				
I am the:		<u></u>	*			<del></del>	:
☐ Applicant/Inv	ventor.						:
	record of the entire interest. See 37 CFR 3. ider 37 CFR 3.73(b) is enclosed. (Form PTC					:	
	SIGNATURE of Applica		ee of Reco	rd	A I		
Signature	Allan ASA		Date		March 11,	2005	
Name	Jeliney A. Hagehah, Reg. No. 33 175	Tel	ephone	(650) 80		2000	
Title and Company	Assistant Secretary of Theravance, Inc.		Spriorie	,000,00	- U-100		
NOTE: Signatures of a	If the inventors or assignees of record of the entire	Interest or their	representati	ve(s) are	required. Subm	tit multiple for	ns if
Total of	re is required, see below*.  forms are submitted.	· · · · · · · · · · · · · · · · · · ·		.,			

This collection of Information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to site (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.